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nfluence of Diabetes and Diabetes-Gender
nteraction on the Risk of Death in Patients
ospitalized With Congestive Heart Failure
da Gustafsson, MD, PHD,* Bente Brendorp, MD, PHD,† Marie Seibæk, MD, PHD,†
ans Burchardt, MD,† Per Hildebrandt, MD, PHD,* Lars Køber, MD, PHD,‡
hristian Torp-Pedersen, MD, PHD, FACC, FESC,§ for the DIAMOND Study Group
openhagen, Denmark
OBJECTIVES The purpose of this study was to investigate the influence of diabetes on long-term mortality
in a large cohort of patients hospitalized with heart failure (HF).
BACKGROUND Diabetes is common in HF patients, but information on the prognostic effect of diabetes is
sparse.
METHODS The study is an analysis of survival data comprising 5,491 patients consecutively hospitalized
with new or worsening HF and screened for entry into the Danish Investigations of
Arrhythmia and Mortality on Dofetilide (DIAMOND). Screening, which included obtain-
ing an echocardiogram in 95% of the patients, took place at Danish hospitals between 1993
and 1995. The follow-up time was five to eight years.
RESULTS A history of diabetes was found in 900 patients (16%), 41% of whom were female. Among
the diabetic patients, 755 (84%) died during follow-up, compared with 3,200 (70%) among
the non-diabetic patients, resulting in a risk ratio (RR) of death in diabetic patients of 1.5
(95% confidence interval [CI] 1.4 to 1.6, p  0.0001). In a multivariate analysis, the RR of
death in diabetic patients was 1.5 (CI 1.3 to 1.76, p  0.0001), but a significant interaction
between diabetes and gender was found. Diabetes increased the mortality risk more in women
than in men, with the RR for diabetic men being 1.4 (95% CI 1.3 to 1.6, p  0.0001) and
1.7 for diabetic women (95% CI 1.4 to 1.9, p  0.0001). The effect of diabetes on mortality
was similar in patients with depressed and normal left ventricular systolic function.
CONCLUSIONS Diabetes is a potent, independent risk factor for mortality in patients hospitalized with HF.
The excess risk in diabetic patients appears to be particularly prominent in females. (J Am
Coll Cardiol 2004;43:771–7) © 2004 by the American College of Cardiology Foundations
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siabetes mellitus is common in patients with heart failure
HF). In surveys and clinical trials of HF, the prevalence of
iabetes ranges from 10% to more than 30% (1). When
atients with pre-diabetic glucose abnormalities are included,
he prevalence exceeds 40% (2). Information on the prognosis
n diabetic patients with HF is sparse. Most of the available
nformation is the result of post-hoc analysis of randomized
rials in myocardial infarction (MI) and congestive HF (CHF).
rom analyses of studies in MI, it is well known that patients
ith diabetes have an increased mortality, which is largely
ttributable to their higher risk of developing post-MI HF
3–8). This increased risk of diabetes seems to be particularly
vident in patients treated with insulin (3,6,9) or in those who
re female (3,9). In the community setting, an increased
ncidence of HF has been reported in diabetic subjects, with
emale diabetic patients having a particularly increased risk of
eveloping HF (10). The Framingham studies have demon-
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ospital; †Department of Cardiology P, Gentofte University Hospital; and ‡Division
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eart Foundation (grant no. 98-2-3-33-22641).
Manuscript received May 3, 2003; revised manuscript received November 4, 2003,dccepted November 26, 2003.trated the importance of diabetes for long-term mortality in
F patients in the community (11). With regard to random-
zed studies, diabetes was found to be an independent risk
actor for mortality and morbidity in both symptomatic and
symptomatic HF in the Studies Of Left Ventricular Dysfunc-
ion (SOLVD) (12). However, in terms of consecutive patients
ospitalized with HF, no contemporary analysis on long-term
rognosis in diabetic subjects exists. We used a large database
f consecutive hospitalizations for HF to study the influence of
iabetes on long-term prognosis and to evaluate the impact of
ther risk factors, particularly gender, on the prognosis in
iabetic subjects.
ETHODS
atient population. The current study is an analysis of
urvival data comprising 5,491 patients screened for entry
nto the Danish Investigations of Arrhythmia and Mortal-
ty on Dofetilide in Congestive Heart Failure—the
IAMOND-CHF trial. Originally 5,548 patients were
creened, but 57 patients were excluded from this study
ecause follow-up was impossible due to misrecorded per-
onal data. The DIAMOND trial was a multicenter, ran-
omized, double-blinded, placebo-controlled study of the
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Prognosis of Diabetic Patients With HF March 3, 2004:771–7fficacy of a novel class III antiarrhythmic agent, dofetilide,
n patients with acute MI or CHF. Details of the DIA-
OND study design (13) and results of the DIAMOND-
HF trial (14) have been published previously. The
4 Danish hospitals participating in the DIAMOND-CHF
tudy screened all patients admitted consecutively to their
enters with new or worsening HF in the period between
ovember 1993 and December 1995. In Denmark, HF
atients are admitted to approximately 60 different hospi-
als, implying that more than half of the potential Danish
ospitals participated in the study. Small county hospitals
nd university teaching hospitals participated in the study,
nd as such, it can be anticipated that the study population
s highly representative of hospitalized HF patients in
enmark.
The patients should have been in New York Heart
ssociation (NYHA) functional class III or IV at some time
ithin the preceding month to be eligible for the
IAMOND-CHF study. Patients with acute MI within
even days before screening were excluded from the CHF
art of the DIAMOND study. The screening procedure
onsisted of a clinical history, a physical examination, and an
chocardiogram, which was recorded on videotape locally
nd evaluated in a central laboratory. The wall motion index
WMI), with use of a 16-segment model of the left ventricle
LV), was calculated using a reverse scoring system (15).
MI multiplied by 30 gives a rough estimate of percent left
entricular ejection fraction (LVEF). Left ventricular sys-
olic function was obtained in 95% of the patients. New-
nset CHF was defined as a CHF duration 1 month.
The diagnosis of diabetes was based on a self-report by
he patient or by documentation in the patient’s medical
ecords. Diabetic subjects were classified according to both
he types of diabetes (I or II) and the antidiabetic treatment
egimen (diet alone, oral hypoglycemic agents, or insulin).
atients receiving both insulin and oral hypoglycemic agents
ere classified as treated with insulin.
Survival status was obtained from the Danish Central
ersonal Registry in July 2002, 8.5 years after screening of
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CHF  congestive heart failure
CI  confidence interval
DIAMOND  Danish Investigations of Arrhythmia and
Mortality on Dofetilide trial
HF  heart failure
ICD-9-CM  International Classification of Diseases-
Ninth Revision-Clinical Modification
LV  left ventricle/ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
NYHA  New York Heart Association
RR  risk ratio
WMI  wall motion indexhe first patient. The minimum follow-up time was five nears. Four patients emigrated during follow-up, and they
ere censored at the time they left Denmark.
tatistics. Discrete variables were compared using the chi-
quare test, and continuous variables with the rank-sum test.
ortality curves were generated using Kaplan-Meier sur-
ival estimates. Multivariate analysis of mortality was made
sing Cox proportional hazards models. Covariates consid-
red of potential prognostic impact by the authors were
ntered into the model. The assumptions of proportional
azards and linearity with regard to continuous variables
ere met for all variables studied. The interaction between
iabetes and other risk factors (age, gender, WMI, history
f ischemic heart disease, and history of hypertension) was
ested by likelihood ratio test. The only relevant interaction
ound was between diabetes and gender. For this reason,
eparate variables were used for diabetes in males and
emales. Significance was accepted at p  0.05. All calcu-
ations were made using the Statistical Analysis System
oftware (SAS Institute, Cary, North Carolina).
thics. The study was conducted in accordance with the
eclaration of Helsinki II and was approved by the Central
anish Ethics Committee. All patients gave their written,
nformed consent before screening.
ESULTS
atient characteristics. Almost all patients were Cauca-
ian (99.9%). A history of diabetes was found in 900 (16%)
f the 5,491 patients. Type I diabetes accounted for 75 cases
8%) and type II for 825 cases (92%). In the diabetic group
s a whole, 24% were treated with insulin, 51% with oral
ypoglycemic agents, and 25% with diet alone. The median
ime since diagnosis of diabetes was 7.1 years. The baseline
haracteristics of patients with and without a history of
iabetes are presented in Table 1. The duration of HF
aried considerably in both groups, but the median duration
as found to be longer for the diabetic group. Compared
ith non-diabetic patients, diabetic patients had a higher
requency of arterial hypertension and known ischemic heart
isease. Left ventricular systolic function was slightly more
mpaired in patients with than in patients without diabetes.
ystolic dysfunction, defined as WMI 1.2 (corresponding
o LVEF 35%), was present in 54% of the diabetic
ubjects and in 45% of the non-diabetic subjects. Diabetic
atients received more diuretics, digoxin, and angiotensin-
onverting enzyme (ACE) inhibitors, reflecting their higher
requency of previous cardiovascular disease.
haracteristics of diabetic women compared with dia-
etic men. Compared with diabetic men, diabetic women
ere older and had a longer duration of diabetes and a lower
ody mass index. The women smoked less and had a lower
requency of previous MI. Despite having similar NYHA
unctional class distribution and a higher use of diuretics,
he women had better systolic function (Table 2). Similar
ifferences between men and women were found among
on-diabetic patients (Table 3).
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March 3, 2004:771–7 Prognosis of Diabetic Patients With HFortality. Among the diabetic patients, 755 (84%) died
uring follow-up, compared with 3,200 (70%) among the
on-diabetic patients (Fig. 1). Crude one-month and one-
ear mortality rates for patients without diabetes were 5%
nd 23%, respectively. The corresponding numbers for
atients with diabetes were 7% and 31%. When evaluated in
univariate model, the risk ratio (RR) of death in diabetic
atients compared with non-diabetic patients was 1.5 (95%
onfidence interval [CI] 1.4 to 1.6, p  0.0001). To
nvestigate whether the increased mortality in patients with
iabetes reflected a higher prevalence of concomitant risk
Table 1. Baseline Characteristics of 5,491 Pati
Diabet
(n  90
Age (yrs) 73 (55–
Male gender (%) 59
Body mass index (kg/m2) 26 (20–
Smoking (%) 29
Clinical history
Ischemic heart disease (%) 64
Previous AMI (%) 39
Treated hypertension (%) 30
Atrial fibrillation (%) 27
Valvular heart disease (%) 3.0
CHF duration (months) 12 (0.07–
New-onset CHF (%) 30
WMI 1.2 (0.6–
NYHA class III or IV (%) 64
Medication on admission
Beta-blockers (%) 13
ACE inhibitors (%) 37
Diuretics (%) 84
Digoxin (%) 43
Continuous variables are presented as the median value (5th
ACE  angiotensin-converting enzyme; AMI  acute m
New York Heart Association; WMI  wall motion index.
Table 2. Baseline Characteristics of 900 Diabe
Wom
(n 
Age (yrs) 75 (57
Body mass index (kg/m2) 26 (19
Smoking (%) 22
Clinical history
Ischemic heart disease (%) 62
Previous AMI (%) 32
Treated hypertension (%) 32
Atrial fibrillation (%) 25
Valvular heart disease (%) 3.
CHF duration (months) 20 (0.07
Diabetes duration (months) 8.0 (0.9
WMI 1.4 (0.6
NYHA class III or IV (%) 63
Medication on admission
Beta-blockers (%) 14
ACE inhibitors (%) 32
Diuretics (%) 87
Digoxin (%) 44
Insulin (%) 28
Continuous variables are presented as the median value (5th
Abbreviations as in Table 1.actors, a multivariate analysis, including age, gender, smok-
ng, history of ischemic heart disease, previous MI, arterial
ypertension, atrial fibrillation, NYHA functional class, and
MI as covariates, was performed. The RR of death in
iabetic patients in this model was 1.5 (95% CI 1.3 to 1.6,
 0.0001) (Table 4). Unfortunately, information on body
ass index was missing for 791 patients (14%); therefore,
his variable was not included in the multivariate model.
dding body mass index to the model, however, did not
lter the results significantly. Similarly, data on new-onset
HF was missing for 437 patients (8%), and the addition of
With and Without a History of Diabetes
Non-Diabetics
(n  4,591) p Value
73 (52–86) 0.54
60 0.40
25 (19–34) 0.0001
35 0.0003
55 0.0001
36 0.11
23 0.0001
24 0.06
3.9 0.18
6 (0.07–120) 0.0001
41 0.0001
1.4 (0.6–2.0) 0.0001
63 0.72
13 0.62
25 0.0001
71 0.0001
31 0.0001
th percentiles).
dial infarction; CHF  congestive heart failure; NYHA 
atients According to Gender
Men
(n  530) p Value
71 (54–83) 0.0001
27 (21–35) 0.04
34 0.0001
66 0.16
44 0.0005
28 0.15
28 0.44
3.0 0.97
) 12 (0.07–144) 0.31
) 6.6 (0.4–25.7) 0.02
1.1 (0.5–2.0) 0.0001
64 0.57
13 0.96
40 0.01
82 0.04
43 0.66
21 0.03
th percentiles).ents
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85)
36)
156)
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Prognosis of Diabetic Patients With HF March 3, 2004:771–7his variable, likewise, did not change the independent
mpact of diabetes on mortality (RR 1.4, p  0.0001), nor
as the result changed significantly by the addition of
reatment with ACE inhibitors, beta-blockers, or digoxin or
hether or not the patients were included in the random-
zed DIAMOND study. In the former multivariate model
including randomization status and treatment with ACE
nhibitors, beta-blockers, or digoxin) and in a model includ-
ng only age, diabetes, and gender, a significant interaction
etween diabetes and gender was found (p  0.03 and
 0.01, respectively). Consequently, a new multivariate
odel including the same nine covariates, besides separate
ariables for diabetes in men and diabetes in women, was
reated. This model revealed that the interaction between
iabetes and gender reflected that diabetes increased the
Table 3. Baseline Characteristics of 4,591 Non
Wom
(n  1,
Age (yrs) 75 (56–
Body mass index (kg/m2) 24 (18–
Smoking (%) 28
Clinical history
Ischemic heart disease (%) 51
Previous AMI (%) 28
Treated hypertension (%) 26
Atrial fibrillation (%) 22
Valvular heart disease (%) 5.0
CHF duration (months) 5 (0.07–
WMI 1.7 (0.6
NYHA class III or IV (%) 63
Medication on admission
Beta-blockers (%) 14
ACE inhibitors (%) 20
Diuretics (%) 74
Digoxin (%) 32
Continuous variables are presented as the median value (5th
Abbreviations as in Table 1.
igure 1. Cumulative mortality from all causes in patients with and
ithout diabetes. DM  diabetic patients; DM  non-diabeticfatients.ortality risk more in women than in men, with the RR for
iabetic men being 1.4 (95% CI 1.3 to 1.6, p 0.0001) and
.7 for diabetic women (95% CI 1.4 to 1.9, p  0.0001). In
atients without diabetes, males had a higher mortality, but
he opposite was found for diabetic patients, where the
emales had the highest mortality rate (Fig. 2). During
ollow-up, 70% of the non-diabetic men and 69% of the
on-diabetic women died. The corresponding numbers for
he diabetic men and women were 83% and 85%. Other
ignificant interactions between diabetes and the remaining
arameters in the multivariate model were not found.
To test if the presented results also apply to the subgroup
f HF patients with LV systolic dysfunction, we performed
he same analyses in those who had WMI1.2. Essentially,
e found similar results. Diabetes was an independent risk
actor of death (RR estimate of 1.5) in both the univariate
nd multivariate models. Furthermore, in the multivariate
odel, the interaction between diabetes and gender was also
ignificant (p  0.03).
The group of type I diabetic patients (n  75) was too
mall to allow for separate statistical analysis. Instead, we
nalyzed the mortality data by classifying the diabetic
atients into three subgroups according to the antidiabetic
reatment regimen (diet, tablets, and insulin). Compared
ith the other two groups, the patients in the insulin-
reated group were younger and had a longer duration of
iabetes and a tendency toward a higher frequency of
revious ischemic heart disease and MI. Mortality during
ollow-up was 83% in the diet-treated group, 84% in the
roup treated with tablets, and 86% in the insulin-treated
roup (p  0.59 by log-rank). When the findings were
djusted for the important differences in age and gender,
nsulin therapy was a significant risk factor for mortality
RR 1.39, 95% CI 1.07 to 1.80; p  0.02). However, when
betic Patients According to Gender
Men
(n  2,772) p Value
72 (50–85) 0.0001
26 (20–34) 0.0001
40 0.0001
58 0.0001
42 0.0001
21 0.0004
25 0.01
3.3 0.006
6 (0.07–120) 0.17
1.2 (0.5–2.0) 0.0001
63 0.81
12 0.17
28 0.0001
69 0.002
31 0.49
th percentiles).-Dia
en
819)
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March 3, 2004:771–7 Prognosis of Diabetic Patients With HFf insulin therapy versus diet treatment disappeared
RR 1.18, 95% CI 0.87 to 1.62; p  0.29).
ISCUSSION
ajor results. The present study is the first large investi-
ation providing data on long-term prognosis and LV
ystolic function in diabetic patients derived from a cohort
f consecutive patients hospitalized with HF. In general, a
omparison of studies on diabetes and HF is difficult
ecause of variability in the definition of disease entities.
ost studies, however, define diabetes by history, as was the
ase in our study. The age and gender distribution of our
ohort is similar to those found in contemporary studies of
nselected HF patients (11,16–18). Because the prevalence
f diabetes is highly associated with age and gender, this
gure should be compared with other studies of a relatively
nselected nature. The diabetes frequency of the present
tudy (16%) is close to the findings in a French survey (19%)
17), in a British study (16%) (18), and in the earlier
ramingham Heart Study (19%) (11), but is somewhat less
han in contemporary U.S. cohorts, where the frequencies
re above 30% (19,20). This discrepancy probably reflects
he difference in the diabetes prevalence between Europe
nd the U.S.
Long-term mortality in diabetic patients from HF co-
orts has only been investigated in a limited number of
tudies. Among 652 patients from the Framingham Heart
tudy with new-onset of HF and a mean follow-up of 3.9
ears, diabetes emerged as a risk factor for mortality (11).
his was also the case in a large Scottish cohort study (16).
owever, the interpretation of this study is difficult, as
iabetes was defined by International Classification of
igure 2. Cumulative mortality from all causes in patients with and without
iabetes for each gender. DM  diabetic patients; DM  non-diabetic
atients; F  females; M  males.iseases-Ninth Revision-Clinical Modification (ICD-9- tM) codes, resulting in a diabetes prevalence of only 3%. In
prospective cohort of 435 patients admitted to a hospital
ith HF, diabetes had no impact on one-year mortality
19).
Additional information on the prognostic influence of
iabetes can be obtained from a few studies in selected
opulations with HF. In the SOLVD trials and registry,
omprising patients with LV dysfunction, diabetes was
ound to be an independent risk factor of long-term mor-
ality and HF-related hospitalizations, with the adjusted RR
or mortality being 1.3 (12). In a hospitalized HF popula-
ion of patients 65 years old, diabetes requiring insulin
reatment was an independent predictor of long-term mor-
ality (21). Diabetes determined by ICD-9-CM codes and
djusted for age and gender revealed a 20% increased
ong-term mortality in a large investigation of hospital
ecords in older adults (67 years old) with HF (22). In
ontrast, diabetes had no prognostic impact on long-term
ortality in the Cardiac Insufficiency BIsoprolol Study II
CIBIS-II), which included HF patients in NYHA func-
ional class III or IV and with LVEF 35% (23). Likewise,
iabetes had no prognostic value in a trial of 471 patients
ith advanced HF (24). The present study adds to infor-
ation on the prognosis of consecutive hospitalized HF
atients, showing that diabetic symptomatic patients both
ith and without LV dysfunction have about a 50%
ncreased mortality rate compared with patients without
iabetes, independent of conventional risk factors.
The cause of the increased risk in patients with diabetes
s not known. Most likely, a higher prevalence of hyperten-
ion and ischemic heart disease involving more widespread
nd distal coronary arteriosclerosis plays an important role.
he existence of a specific diabetic cardiomyopathy giving
ise to LV diastolic dysfunction is another factor of potential
egative influence on outcome (25). Also, we cannot ex-
lude the possibility of a selection bias, implying that the
iabetic patients have HF at a more advanced stage when
ospitalized, and that such a situation is not completely
ccounted for by adding WMI and NYHA functional class
o the regression models.
nteraction between diabetes and other variables. An
mportant finding in this study is the diabetes–gender
nteraction. Previous reports have indicated that diabetes
as a greater impact on women than on men with regard to
able 4. Long-Term Mortality Risk in Diabetic Patients
ompared With Non-Diabetic Patients: Results of Univariate
nd Multivariate Models
RR (95% CI) p Value
nivariate 1.5 (1.4–1.6) 0.0001
ultivariate model 1* 1.5 (1.4–1.7) 0.0001
ultivariate model 2† 1.5 (1.3–1.6) 0.0001
Including age and gender as covariates. †Including age, gender, smoking, history of
schemic heart disease, previous myocardial infarction, arterial hypertension, atrial
brillation, New York Heart Association class, and wall motion index as covariates.
CI  confidence interval; RR  risk ratio.he prognosis of HF, but a formal interaction analysis was
n
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Prognosis of Diabetic Patients With HF March 3, 2004:771–7ot applied in these studies (3,9,11). Also, there seems to be
similar experience with regard to the prognosis in coronary
eart disease, although it is not a consistent finding (26,27).
ery little is known about the mechanism underlying the
ender difference in risk from diabetes in HF patients. It is
ossible that part of the explanation is a clustering of risk
actors in diabetic women, which we were not able to
ontrol for, such as the level of high-density lipoprotein and
polipoprotein B (26,28). Angiographic data suggest a
endency toward more extensive coronary artery disease in
iabetic women (29). Data from human studies in aortic
tenosis and hypertension have revealed gender differences
n LV hypertrophic responses (30). Moreover, in individuals
ithout cardiovascular disease, it has been found that
iabetes in women is independently associated with in-
reased LV wall thickness and mass (31). This may result in
higher frequency of LV diastolic dysfunction, explaining
he relative mismatch between symptoms and systolic func-
ion in women. However, the impact of isolated or coexist-
ng diastolic dysfunction on prognosis is unknown. Lastly, it
s possible that diabetic women with HF are admitted to the
ospital only at a later stage, thereby introducing a selection
ias (30).
In the present study, we did not find a significant
nteraction between diabetes and HF etiology (i.e., ischemic
s. non-ischemic HF). This is in contrast to recently
ublished, important results from SOLVD (32), where it
as found that diabetes was associated with an increased
ortality only in patients with underlying ischemic heart
isease. The reason for the discrepancy between the two
tudies is not clear. However, it should be considered that a
efinite diagnosis of ischemic heart disease has not been
ttempted in all patients in either study, and the condition
s therefore likely to be underdiagnosed. Furthermore, a
ajor difference between the studies exists in that a large
art of the population in the study by Dries et al. (32) was
ecruited from the prevention arm of SOLVD. These
atients, per definition, had systolic dysfunction but no
linical HF, and thus the results may not be comparable to
hose obtained in a population of patients hospitalized with
F.
In contrast to what has been described in studies of MI,
e did not find a significantly higher mortality rate in the
nsulin-treated patients compared with the non-insulin-
reated diabetic patients. However, there was a trend toward
higher mortality rate in insulin-treated subjects when age
nd other risk factors where controlled for. It is possible that
he lack of a significant difference in mortality between the
iabetic groups can simply be the result of a type 2 statistical
rror (i.e., the low number of patients treated with insulin).
tudy limitations. The limitations of this study relate
ainly to the definitions of diabetes and HF. Unfortunately,
o data on the glycometabolic state were available. It can be
nticipated that a significant proportion of the non-diabetic
atients have undiagnosed diabetes. If these patients also
ave an increased mortality risk, the presented results areikely to underestimate the real difference between patients
ith and without diabetes. With regard to the definition of
F, this diagnosis was based on clinical judgment by the
nvestigators, but it was a requirement that the patients had
o be in NYHA functional class III or IV within the
receding month. It is possible that the study includes some
atients who, if reevaluated, would turn out not to suffer
rom HF but from other conditions such as pulmonary
isease. Therefore, it is reassuring that when performing the
urvival analysis including only patients with at least mod-
rately depressed LV systolic function, similar results were
btained.
A point of concern is the significant baseline differences
etween diabetic and non-diabetic patients, which may
onfound the survival analyses. Efforts have been made in
he multivariate analyses to correct for potential confound-
ng, but one cannot exclude the possibility that other
onfounders that we were not able to include in the models
xist.
onclusions. The present study demonstrates that patients
ith diabetes represent a high-risk group in HF.
cknowledging this finding is important because therapy
ith ACE inhibitors (33) and beta-blockers (34) seems to
ave at least the same relative effect in these patients and,
hereby, a greater absolute effect when compared with
on-diabetic patients. In conclusion, diabetes is an impor-
ant risk factor for mortality in HF patients, and the effect
f diabetes appears to be most prominent in females.
eprint requests and correspondence: Dr. Ida Gustafsson,
epartment of Cardiology and Endocrinology, Frederiksberg
ospital, Nordre Fasanvej 57, DK-2000 Frederiksberg, Denmark.
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